以 P-TEFb 为靶点重新激活潜伏的 HIV：现在有两种药物可供选择。
P-TEFb as a target to reactivate latent HIV: two Brds are now in hand.
机构信息
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
出版信息
Cell Cycle. 2013 Feb 1;12(3):392-3. doi: 10.4161/cc.23556. Epub 2013 Jan 16.
Abstract
Comment on: Boehm D, et al. Cell Cycle 2013; 12(3): In this issue.
摘要
评论
Boehm D 等人。细胞周期 2013;12(3)：本期特刊。
相似文献
1
P-TEFb as a target to reactivate latent HIV: two Brds are now in hand.以 P-TEFb 为靶点重新激活潜伏的 HIV：现在有两种药物可供选择。
Cell Cycle. 2013 Feb 1;12(3):392-3. doi: 10.4161/cc.23556. Epub 2013 Jan 16.
2
A new BET on the control of HIV latency.对控制HIV潜伏的新赌注。
Cell Cycle. 2013 Feb 15;12(4):545-6. doi: 10.4161/cc.23679. Epub 2013 Jan 31.
3
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.BET 溴结构域靶向化合物通过一种不依赖 Tat 的机制重新激活潜伏状态的 HIV。
Cell Cycle. 2013 Feb 1;12(3):452-62. doi: 10.4161/cc.23309. Epub 2012 Feb 1.
4
Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation.周期素依赖性激酶 7（CDK7）介导的 CDK9 激活环磷酸化促进了 Tat 与 P-TEFb 的组装以及前病毒 HIV 的重新激活。
J Biol Chem. 2018 Jun 29;293(26):10009-10025. doi: 10.1074/jbc.RA117.001347. Epub 2018 May 9.
5
The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency.KAT5-乙酰化组蛋白 4-Brd4 轴沉默 HIV-1 转录并促进病毒潜伏。
PLoS Pathog. 2018 Apr 23;14(4):e1007012. doi: 10.1371/journal.ppat.1007012. eCollection 2018 Apr.
6
HIV latency reversing agents act through Tat post translational modifications.HIV 潜伏逆转剂通过 Tat 翻译后修饰起作用。
Retrovirology. 2018 May 11;15(1):36. doi: 10.1186/s12977-018-0421-6.
7
A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.一种查尔酮衍生物通过激活 P-TEFb 和促进病毒启动子上的 Tat-SEC 相互作用来重新激活潜伏的 HIV-1 转录。
Sci Rep. 2017 Sep 6;7(1):10657. doi: 10.1038/s41598-017-10728-w.
8
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.BET 溴结构域抑制剂 JQ1 通过拮抗 Brd4 对 Tat 转录激活的抑制作用来激活 HIV 潜伏。
Nucleic Acids Res. 2013 Jan 7;41(1):277-87. doi: 10.1093/nar/gks976. Epub 2012 Oct 18.
9
Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription.在产生负责P-TEFb介导的HIV-1转录的tat刺激的Cdk9/细胞周期蛋白T1异二聚体过程中对激酶特异性伴侣蛋白途径的需求。
J Biol Chem. 2000 Jan 7;275(1):279-87. doi: 10.1074/jbc.275.1.279.
10
Relief of two built-In autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter.在人免疫缺陷病毒1型启动子处组装多组分转录延伸复合物需要解除P-TEFb中的两种内在自抑制机制。
Mol Cell Biol. 2000 Aug;20(16):5897-907. doi: 10.1128/MCB.20.16.5897-5907.2000.
引用本文的文献
1
Microglia: The Real Foe in HIV-1-Associated Neurocognitive Disorders?小胶质细胞：HIV-1相关神经认知障碍中的真正敌人？
Biomedicines. 2021 Jul 30;9(8):925. doi: 10.3390/biomedicines9080925.
2
Post-translational Modification-Based Regulation of HIV Replication.基于翻译后修饰的HIV复制调控
Front Microbiol. 2018 Sep 11;9:2131. doi: 10.3389/fmicb.2018.02131. eCollection 2018.
3
A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association.一种新型溴结构域抑制剂通过与BRD4特异性结合逆转HIV-1潜伏，以促进Tat与P-TEFb结合。
Front Microbiol. 2017 Jun 7;8:1035. doi: 10.3389/fmicb.2017.01035. eCollection 2017.
4
Molecular mechanisms of HIV latency.HIV潜伏的分子机制。
J Clin Invest. 2016 Feb;126(2):448-54. doi: 10.1172/JCI80565. Epub 2016 Jan 5.
5
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.BET 和 HDAC 抑制剂诱导相似的基因和生物学效应，并协同作用以杀死 Myc 诱导的小鼠淋巴瘤。
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2721-30. doi: 10.1073/pnas.1406722111. Epub 2014 Jun 16.
6
Chromatin targeting drugs in cancer and immunity.染色质靶向药物在癌症和免疫中的作用
Genes Dev. 2013 Aug 15;27(16):1731-8. doi: 10.1101/gad.221895.113.
本文引用的文献
1
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.BET 溴结构域靶向化合物通过一种不依赖 Tat 的机制重新激活潜伏状态的 HIV。
Cell Cycle. 2013 Feb 1;12(3):452-62. doi: 10.4161/cc.23309. Epub 2012 Feb 1.
2
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.BET 溴结构域抑制剂 JQ1 通过拮抗 Brd4 对 Tat 转录激活的抑制作用来激活 HIV 潜伏。
Nucleic Acids Res. 2013 Jan 7;41(1):277-87. doi: 10.1093/nar/gks976. Epub 2012 Oct 18.
3
Reactivation of latent HIV-1 by inhibition of BRD4.抑制 BRD4 使潜伏的 HIV-1 重新激活。
Cell Rep. 2012 Oct 25;2(4):807-16. doi: 10.1016/j.celrep.2012.09.008. Epub 2012 Oct 4.
4
Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein.Bromodomain 和额外末端（BET）溴结构域抑制通过从 7SK 小核核糖核蛋白中瞬时释放正转录伸长因子 b（P-TEFb）来激活转录。
J Biol Chem. 2012 Oct 19;287(43):36609-16. doi: 10.1074/jbc.M112.410746. Epub 2012 Sep 5.
5
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.BET 溴结构域抑制作为一种新型的 HIV-1 重新激活策略。
J Leukoc Biol. 2012 Dec;92(6):1147-54. doi: 10.1189/jlb.0312165. Epub 2012 Jul 16.
6
Analysis of the human endogenous coregulator complexome.人类内源性共激活因子复合物组分析。
Cell. 2011 May 27;145(5):787-99. doi: 10.1016/j.cell.2011.05.006.
7
The super elongation complex (SEC) and MLL in development and disease.超级延伸复合物（SEC）和 MLL 在发育和疾病中的作用。
Genes Dev. 2011 Apr 1;25(7):661-72. doi: 10.1101/gad.2015411.
8
Selective inhibition of BET bromodomains.选择性抑制 BET 溴结构域。
Nature. 2010 Dec 23;468(7327):1067-73. doi: 10.1038/nature09504. Epub 2010 Sep 24.
9
Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4(+) T lymphocytes.静息和活化的CD4(+) T淋巴细胞中Cdk9 T环磷酸化的特征分析
J Leukoc Biol. 2009 Dec;86(6):1345-50. doi: 10.1189/jlb.0509309. Epub 2009 Sep 10.
Zotero 插件